These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26767080)

  • 1. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.
    Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 Feb; 8(2):116-25. PubMed ID: 26767080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Ipragliflozin for Reducing Hemoglobin A1c in Patients With a Shorter Type 2 Diabetes Duration: Interim Report of the ASSIGN-K Study.
    Iemitsu K; Kawata T; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Sep; 9(9):793-801. PubMed ID: 28811858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.
    Iemitsu K; Iizuka T; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Kawata T; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyagi S; Hoshino K; Ishikawa M; Obana M; Sasai N; Kaneshige H; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2016 May; 8(5):373-8. PubMed ID: 27081422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.
    Kawata T; Iizuka T; Iemitsu K; Takihata M; Takai M; Nakajima S; Minami N; Umezawa S; Kanamori A; Takeda H; Ito S; Kikuchi T; Amemiya H; Kaneshiro M; Mokubo A; Takuma T; Machimura H; Tanaka K; Asakura T; Kubota A; Aoyanagi S; Hoshino K; Ishikawa M; Matsuzawa Y; Obana M; Sasai N; Kaneshige H; Minagawa F; Saito T; Shinoda K; Miyakawa M; Tanaka Y; Terauchi Y; Matsuba I
    J Clin Med Res; 2017 Jul; 9(7):586-595. PubMed ID: 28611859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
    Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
    Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipragliflozin Add-on Therapy to a GLP-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes (AGATE): A 52-Week Open-Label Study.
    Ishihara H; Yamaguchi S; Nakao I; Sakatani T
    Diabetes Ther; 2018 Aug; 9(4):1549-1567. PubMed ID: 29926400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.
    Kashiwagi A; Kazuta K; Yoshida S; Nagase I
    J Diabetes Investig; 2014 Jul; 5(4):382-91. PubMed ID: 25411597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evidence for long-term safety and effectiveness of ipragliflozin in treatment-naïve versus non-naïve Japanese patients with type 2 diabetes mellitus: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Maegawa H; Tobe K; Nakamura I; Uno S
    Diabetol Int; 2021 Oct; 12(4):430-444. PubMed ID: 34567926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial.
    Sawano F; Kamei N; Miyahara M; Kobuke K; Nakanishi S; Nagano C; Nojima H; Maeda S; Watanabe H; Kishimoto R; Yamashita M; Hamaoka A; Mukai K; Tsuboi T; Mochizuki H; Nakashima R; Sakashita Y; Morishita H; Kitamura T
    Diabetol Int; 2021 Oct; 12(4):364-378. PubMed ID: 34567919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin.
    Kato M; Sakai K; Saito K; Tsutsui K; Yamashita S; Kato N
    Diabetol Int; 2017 Aug; 8(3):275-285. PubMed ID: 30603333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
    Nakamura I; Maegawa H; Tobe K; Uno S
    Expert Opin Pharmacother; 2021 Feb; 22(3):373-387. PubMed ID: 33012212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
    Shestakova MV; Wilding JPH; Wilpshaar W; Tretter R; Orlova VL; Verbovoy AF
    Diabetes Res Clin Pract; 2018 Dec; 146():240-250. PubMed ID: 30391333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial.
    Min KW; Ku BJ; Lee JH; Kim MS; Ahn KJ; Lee MK; Kokubo S; Yoshida S; Cho HJ; Cha BS
    Diabetes Metab J; 2017 Apr; 41(2):135-145. PubMed ID: 28447440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
    Takasu T; Hayashizaki Y; Tahara A; Kurosaki E; Takakura S
    Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):87-93. PubMed ID: 25311502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT).
    Tanaka A; Imai T; Toyoda S; Sugimoto K; Yoshida R; Furuta M; Node K;
    Diabetol Metab Syndr; 2023 Jul; 15(1):152. PubMed ID: 37415229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study.
    Ueno H; Nakazato H; Ebihara E; Noma K; Kawano T; Nagamine K; Sakoda H; Nakazato M
    Diabetes Ther; 2018 Feb; 9(1):403-411. PubMed ID: 29322485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.
    Kashiwagi A; Yoshida S; Kawamuki K; Nakamura I; Kazuta K; Ueyama E; Takahashi H; Akiyama N; Kondo Y; Ogihara T
    Diabetol Int; 2017 Mar; 8(1):76-86. PubMed ID: 30603310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
    Ohta A; Kato H; Ishii S; Sasaki Y; Nakamura Y; Nakagawa T; Nagai Y; Tanaka Y
    Expert Opin Pharmacother; 2017 Oct; 18(14):1433-1438. PubMed ID: 28770629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.